查詢結果分析
相關文獻
- Zafirlukast Improves Pulmonary Function in Patients with Moderate Persistent Asthma Receiving Regular Inhaled Steroids: A Prospective Randomized Control Study
- 氣喘新療法--白三烯素的相關研究
- 抗白三烯素藥物--氣喘治療的新方法
- Release of Leukotrienes by the Calcium Ionophore A23187 from Porcine Lung Tissue in Vitro
- 日糧脂肪酸對仔豬肺組織白三烯素生成之影響
- 長效吸入型乙二型交感神經興奮劑在治療阻塞性肺病的臨床應用
- The Biologic Effects on Bone Cell Metabolism of Parathyroid Hormone, Calcitonin, Prostaglandins and Leukotrienes
- Inhibitory Effect of Gold Sodium Thiomalate on Leukotriene Production
- The Production of Leukotriene C[feb2] from Gastric Cancer Cells and Normal Gastric Mucosal Cells
- The Effect of NaCL on Leukotriene Production in Human Polymorphonuclear Leukocytes
頁籤選單縮合
題名 | Zafirlukast Improves Pulmonary Function in Patients with Moderate Persistent Asthma Receiving Regular Inhaled Steroids: A Prospective Randomized Control Study=Zafirlukast對規律使用吸入性類固醇的中度持續性氣喘病人的肺功能的改善:一個前瞻性的隨機控制研究 |
---|---|
作者 | 黃崇仁; 王圳華; 劉文德; 楊美貞; 林鴻銓; 余志騰; 蕭嘉榮; 唐家駿; 楊朝凱; 郭漢彬; | 書刊名 | 長庚醫學 |
卷期 | 26:8 2003.08[民92.08] |
頁次 | 頁554-560 |
分類號 | 418.263 |
關鍵詞 | 尖峰吐氣流速值; 聖喬治呼吸評量表; 白三烯素; Peak expiratory flow rate; St George's respiratory questionnaire; Leukotriene; |
語文 | 英文(English) |
中文摘要 | 背景:白三烯素接合器的拮抗劑已經皮研發用來治療慢性氣喘。 方法:本篇研究在探討Zafirlukast是否會改善氣端病人的尖峰吐氣流速值和臨床症狀。31位固定使用吸入型類固醇的中度持續性氣喘的病人被隨機分配成實驗組(17位病人)和對照組(14位病人),實驗組接受四週的Zafirlukast,每峋兩次一次20毫克,對照組則接受吸入型類固醇和安慰劑,每天清晨和傍晚的尖峰味氣流速值,治療前後的聖喬治呼吸評量表,血清當中的免疫球蛋白E和尿液中的白三烯素E4被測量來評估治療效果。 結果:經過四個星期的治療,在實驗組清晨的尖峰吐氣流速值明顯的由314.4±26.6進步到340.6±18.3公升/分童,而對照組則沒有明顯的改變。在實驗組中病人的聖喬呼吸評量表的症狀分數也有明顯的改善從48.6±4.6到33.8±4.7,萬對照組則沒有明顯的差別。 |
英文摘要 | Backgournd: Zafirlukast is a leukotriene receptor antagonist and was invented to treat patients with chronic asthma. Methods: to evaluate whether the zafirlukast improved the peak expiratory flow rate (PEFR) and clinical symptoms, 31 asthmatic patients with moderate persistent asthma who received regular inhaled corticosteroid were randomly divided into the study group (n=17). They received the zafirlukast 20 mg bid for 4 weeks, and the control group (n=14) received a placebo. Daily morning and evening PEFR and St. George’s Respiratory Questionnaire (SGRQ) scoring were recorded respectively. The levels of serum IgE and urine leukotriene E4 before and after treatment were measured using enzyme linked immunosorbent assay and enzyme immunoassay kits. Results: In the zafirlukast treated group, the morning PEFR was significantly improved from 314.4±20.6 to 340.6±18.3 L/min (N=17, P<0.05) after 4 weeks of treatment, while the control group did not show any significant changes. The zfirlukast group had significant improvement in their symptom scores of SGRQ form 48.3±4.6 to 33.8±4.7 (N=17, p<0.05). However, the placebo did not improve the symptom scores. Conclusion: Leukotriene receptor antagonists effectively improved symptoms and benefited lung function for moderate persistent asthmatic patients who had received regular treatments with inhaled steroids. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。